Puma Biotechnology acquires and develops innovative products for the treatment of various forms of cancer.
Puma Biotechnology, Inc., is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of various forms of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. The Company is initially focused on the development of PB-272 (oral neratinib), a potent irreversible tyrosine kinase inhibitor, for the treatment of patients with HER2 positive metastatic breast cancer.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Oct 5, 2011 | Post-IPO Equity | $55M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
H&Q Healthcare Investors | — | Post-IPO Equity |